TY - JOUR
T1 - The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
AU - Zou, Jing
AU - Xie, Xuping
AU - Fontes-Garfias, Camila
AU - Swanson, Kena A.
AU - Kanevsky, Isis
AU - Tompkins, Kristin
AU - Cutler, Mark
AU - Cooper, David
AU - Dormitzer, Philip R.
AU - Shi, Pei-Yong
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.
AB - Initial COVID-19 vaccine candidates were based on the original sequence of SARS-CoV-2. However, the virus has since accumulated mutations, among which the spike D614G is dominant in circulating virus, raising questions about potential virus escape from vaccine-elicited immunity. Here, we report that the D614G mutation modestly reduced (1.7–2.4-fold) SARS-CoV-2 neutralization by BNT162b2 vaccine-elicited mouse, rhesus, and human sera, concurring with the 95% vaccine efficacy observed in clinical trial.
UR - http://www.scopus.com/inward/record.url?scp=85103430539&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103430539&partnerID=8YFLogxK
U2 - 10.1038/s41541-021-00313-8
DO - 10.1038/s41541-021-00313-8
M3 - Article
C2 - 33767200
AN - SCOPUS:85103430539
SN - 2059-0105
VL - 6
JO - npj Vaccines
JF - npj Vaccines
IS - 1
M1 - 44
ER -